Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema
Pressler A, Grosber M, Halle M, Ring J, Brockow K (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 38
Pages Range: 151-153
Journal Issue: 2
DOI: 10.1111/j.1365-2230.2012.04430.x
Abstract
Vibratory angio-oedema is a rare form of physical urticaria characterized by pruriginous weals and angio-oedema at the site of exposure to vibration. Severe treatment-resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti-IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio-oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment-resistant vibratory angio-oedema. © The Author(s). CED © 2012 British Association of Dermatologists.
Involved external institutions
Germany (DE)How to cite
APA:
Pressler, A., Grosber, M., Halle, M., Ring, J., & Brockow, K. (2013). Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clinical and Experimental Dermatology, 38(2), 151-153. https://doi.org/10.1111/j.1365-2230.2012.04430.x
MLA:
Pressler, A., et al. "Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema." Clinical and Experimental Dermatology 38.2 (2013): 151-153.
BibTeX: Download